References

Perioperative apalutamide in high-risk localized prostate cancer

10.1056/nejmoa2603878 · 2026 · External reference

Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer

10.1200/jco.2017.73.9987 · 2017 · External reference

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

10.1016/s0140-6736(21)02437-5 · 2022 · External reference

20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years

10.1056/nejmoa1701830 · 2017 · External reference

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

10.1016/s0140-6736(20)30314-7 · 2020 · External reference

Pelvic lymph node dissection in prostate cancer: update from a randomized clinical trial of limited versus extended dissection

10.1016/j.eururo.2024.10.006 · 2025 · External reference

Improved outcomes with enzalutamide in biochemically recurrent prostate cancer

10.1056/nejmoa2303974 · 2023 · External reference

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

10.1016/s1470-2045(19)30688-6 · 2019 · External reference